Precigen Inc
PGEN
NASDAQ
Biotechnology
$6.10
USD
-0.39 (-6.01%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.33B
Volume 7.9M
About Precigen Inc
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 160 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
CEO
Dr. Helen Sabzevari
HQ
Germantown, MARYLAND, US
Founded
2013
Employees
160
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on PGEN.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
1875.0%
+1876.2 pp
Gross Margin (TTM)
90.7%
+91.4 pp
Operating Margin (TTM)
-46.1%
+2353.4 pp
Net Margin (TTM)
-184.0%
+2684.7 pp
ROE (TTM)
-361.9%
—
Free Cash Flow (TTM)
$-115.22M
—
Financial Snapshot
Revenue
$85.72M
+1875.0%
YoY
Gross Margin
91%
TTM
+13217.3%
YoY
Net Income
$-157.71M
-26.7%
YoY
Operating Cash Flow
$-114.17M
-72.3%
YoY
Key Statistics
Open
$6.32
Previous Close
$6.49
Day Range
$6.08 - $6.39
52 Week Range
$1.80 - $7.32
Volume
7.9M
Average Volume (10 Days)
7.1M
Dividend Yield
—
Valuation Measurement
Market Cap
$2.33B
P/E Ratio (TTM)
—
P/S Ratio (TTM)
27.23
Price / Book
53.57
Financial Highlights
Profit Margin
-184.0%
Return on Assets
-92.6%
Return on Equity
-361.9%
Revenue (TTM)
$85.72M
Net Income (TTM)
$-157.71M
Diluted EPS (TTM)
-$1.10
Total Cash (MRQ)
$16.33M
Levered FCF (TTM)
$-115.22M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
AGIO
Agios Pharmaceuticals Inc
$33.56
▲ +0.3%
ADMA
ADMA Biologics Inc
$9.47
▲ +0.6%
ZBIO
Zenas Biopharma Inc
$29.51
▲ +1.1%
PVLA
Palvella Therapeutics Inc
$156.13
▼ -0.3%
STOK
Stoke Therapeutics Inc
$31.27
▼ -0.1%
MLYS
Mineralys Therapeutics Inc
$25.64
▼ -1.7%
VRDN
Viridian Therapeutics Inc
$22.08
▲ +0.4%
GENB
Generate Biomedicines Inc
$15.64
▲ +4.1%
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 11
Est. EPS
Adjusted consensus estimate
$0.06
Analyst Consensus
Based on 1 analyst ratings
Avg Target: $18.00
(+195.1% upside)
High: $18.00 · Low: $18.00
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%